AbCellera Biologics (NASDAQ: ABCL) shares surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst expectations.

The biotechnology company reported a quarterly loss of $0.12 per share, beating the analyst consensus estimate of a $0.15 loss by 21.05%. This represents an improvement from the $0.13 per share loss reported in the same period last year. More impressively, AbCellera's quarterly sales skyrocketed to $17.084 million, surpassing the analyst consensus estimate of $5.824 million by a staggering 193.31%. This marks a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year.

AbCellera Biologics, known for its AI-powered antibody discovery platform, has been gaining attention in the biotech sector. The company's strong performance this quarter, particularly its ability to more than double its sales year-over-year, suggests growing demand for its innovative technologies. As investors digest this positive earnings surprise, it could potentially lead to revised outlook and increased interest in ABCL stock moving forward.